Can You Take Urolithin A With NMN?

Urolithin A and NMN are two of the most talked-about longevity compounds, and they are often mentioned in the same breath. But they are not interchangeable, and they do not do the same job inside your cells. Here is a clear, evidence-first look at why some people pair them, how the timing tends to work, and where the honest limits of the science sit.

Two different levers on the same system

Almost every conversation about cellular aging eventually lands on the mitochondria, the tiny structures inside your cells that turn food and oxygen into usable energy. Urolithin A and NMN both touch mitochondrial biology, which is why they get grouped together, but they pull on completely different levers. Understanding that distinction is the whole reason a stack can make sense.

Urolithin A is a gut postbiotic. Your microbiome makes it from ellagitannins, the polyphenols found in pomegranates, walnuts and certain berries. Its most-studied job is supporting mitophagy the cellular housekeeping process that identifies worn-out, underperforming mitochondria and recycles them so fresher ones can take over. Think of it as quality control for your cellular power plants. You can read the full background in our urolithin A guide.

NMN (nicotinamide mononucleotide) works upstream of energy production itself. It is a direct precursor to NAD+, a coenzyme that every cell uses to run metabolism, power the enzymes involved in DNA repair, and keep the electron transport chain moving. NAD+ levels tend to decline with age, and the logic behind NMN is straightforward: give the body more raw material and it can maintain healthier NAD+ pools. NMN has its own growing body of human safety and pharmacokinetic research, though like urolithin A it is still an emerging field.

So the simple framing is this: NMN is about supplying the fuel currency (NAD+), while urolithin A is about maintaining the machinery that spends it (the mitochondria themselves). They address different points in the same pathway, which is exactly why people interested in mitochondrial health look at them as complementary rather than redundant. If you want the deeper mechanism on the recycling side, see mitochondrial health.

What the human evidence actually shows for urolithin A

Because SOMA HEALTH makes a urolithin A product, we hold ourselves to citing only real studies and labeling clearly what is human versus preclinical. Here is where urolithin A stands.

Proven in humans

The first-in-human safety work came from Andreux and colleagues in 2019 (Nature Metabolism), which found urolithin A was safe and well tolerated at doses up to 1,000 mg per day and produced a measurable mitochondrial gene-expression signature in humans. Liu, D'Amico and colleagues (2022, JAMA Network Open) followed older adults over roughly four months and reported improvements in muscle endurance, measured as the number of muscle contractions before fatigue. Singh and colleagues (2022, Cell Reports Medicine) studied middle-aged adults across 500 mg and 1,000 mg arms over four months and observed benefits to muscle strength and exercise performance.

Newer human research

A 2025 Nature Aging randomized trial of about 28 days reported that urolithin A supported the mitochondrial health of immune cells in midlife adults, an area of interest often described as inflammaging. A 2024 trial in the Journal of the International Society of Sports Nutrition ran eight weeks in resistance-trained men and looked at endurance and recovery markers, and a 2025 trial in distance runners added to the athletic picture. A 2024 systematic review in Ageing Research Reviews summed up the state of play honestly: the evidence is promising but still emerging, built on relatively short trials with modest participant numbers.

Preclinical only (animal and cell studies)

The foundational science came from Ryu and colleagues (2016, Nature Medicine), who showed urolithin A triggered mitophagy, extended lifespan in the worm C. elegans, and improved muscle function in rodents. That is a landmark study, but it is not human proof. D'Amico and colleagues (2022, Aging Cell) explored joint and cartilage mitochondrial health in osteoarthritis models. Work on skin, gut, brain and heart remains at the early, preclinical stage. When you see those benefits described online, treat them as hypotheses being explored, not established human outcomes.

Why the two are considered complementary

The theoretical case for pairing them rests on the fact that they operate at non-overlapping steps. Fresh, well-maintained mitochondria (the goal urolithin A supports through mitophagy) still need NAD+ to actually generate energy. Conversely, topping up NAD+ raw materials does less good if the mitochondria doing the work are old and inefficient. In principle, one keeps the workforce fresh while the other keeps it fueled. It is a tidy, mechanistically sensible story.

The important honesty here: to our knowledge there is no large, well-powered human trial that has tested the urolithin A plus NMN combination head-to-head against either compound alone and measured a real-world outcome. The complementary logic is grounded in each compound's individual biology, not in a combination trial. That is a meaningful gap, and anyone telling you the stack is proven to outperform a single ingredient is going beyond the evidence. What we can say is that each has its own human safety record within studied doses, and their mechanisms do not obviously conflict.

This is a structure and function discussion, not medical advice, and neither compound is a treatment for any disease. If you have a health condition, take prescription medication, are pregnant or nursing, or are managing anything involving your metabolism, blood sugar or cardiovascular system, talk to your doctor before starting either supplement or combining them. See your healthcare provider, not a supplement label, for anything that touches a diagnosis.

Practical guidance on dose and timing

For urolithin A, the clinically studied range is 500 to 1,000 mg per day, with 1,000 mg sitting at the top of that range. SOMA HEALTH formulates to 1,000 mg per daily serving for that reason. There is no established need to cycle it, and the human trials dosed it daily and continuously. You can go deeper in our how to take urolithin A notes.

NMN dosing in human studies has varied, and the field has not settled on one universally agreed amount, so follow the product label and your clinician's input rather than a number you read on a forum. Many people take NMN in the morning on the theory that it fits the body's natural NAD+ rhythm, though the evidence for a single best time of day is thin.

For a combined routine, a common sensible approach is to take both in the morning, ideally with a meal that contains some fat, since urolithin A is fat-soluble and absorption tends to be steadier with food. Gummies like SOMA HEALTH's are convenient here because they remove the guesswork of measuring powders. Give any routine a fair, consistent run: the urolithin A muscle trials ran roughly four months, so patience matters. Our note on how long urolithin A takes to work sets realistic expectations.

Consistency beats stacking-everything enthusiasm. If you are new to both, some people prefer to start one compound at a time so that if anything feels off, they know which ingredient to adjust. And whatever you choose, buy third-party tested products so the dose on the label is the dose in the jar.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.